Potency and spectrum trends for cefepime tested against 65 746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY Antimicrobial Surveillance Program (1998-2003)

Diagnostic Microbiology and Infectious Disease

Volumn 52, Issue 3, 2005, Pages 265-273

  Sader, Helio S ^a,b   Fritsche, Thomas R ^a   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cefepime; Cephalosporin; Enterobacteriaceae; Pseudomonas aeruginosa; Streptococcus pneumoniae

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; AZTREONAM; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD FLOW; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SENSITIVITY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HEALTH SURVEY; INFORMATION PROCESSING; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA;

EID: 23644445217     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2005.02.003     Document Type: Article

References (19)

1. C. Bantar, L. Bavestrello, D. Curcio, A. Jasovich, R. Absi, H. Bagnulo, A. Famiglietti, P. Garcia, J. Labarca, J. Mera, W. Pedreira, H. Sader, L. Thompson, S. Wey ConsenSur Group Acute community-acquired pneumonia in adults: Guidelines for initial antimicrobial therapy based on local evidence from a South American working group (ConsenSur) J. Chemother. 14 2002 635 636
2. L.B. Barradell, and H.M. Bryson Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use Drugs 47 1994 471 505
3. E. Bouza, and P. Munoz Monotherapy versus combination therapy for bacterial infections Med. Clin. North Am. 84 2000 1357 1389
4. Y. Carmeli, M. Troillet, G.M. Eliopoulos, and M.H. Samore Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents Antimicrob. Agents Chem. 43 1999 1379 1382
5. T.M. Chapman, and C.M. Perry Cefepime: A review of its use in the management of hospitalized patients with pneumonia Am. J. Respir. Medicine 2 2003 75 107
6. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing, 15th informational supplement Document M100-S15 2005 CLSI Wayne (Pa)
7. T.R. Fritsche, H.S. Sader, and R.N. Jones Comparative activity and spectrum of broad spectrum β-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: Report from the SENTRY Antimicrobial Surveillance Program (North America: 2001-2002) Diagn. Microbiol. Infect. Dis. 47 2003 435 440
8. H. Hanberger, D. Diekema, A. Fluit, R. Jones, M. Struelens, R. Spencer, and M. Wolff Surveillance of antibiotic resistance in European ICUs J. Hosp. Infect. 48 2001 161 176
9. A.D. Harris, D. Smith, J.A. Johnson, D.D. Bradham, and M.C. Roghmann Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients Clin. Infect. Dis. 34 2002 340 345
10. E.H. Ibrahim, G. Sherman, S. Ward, V.J. Fraser, and M.H. Kollef The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting Chest 118 2000 146 155
11. R.N. Jones Resistance patterns among nosocomial pathogens. Trends over the past few years Chest 119 2001 397S 404S
12. R.N. Jones, and D.J. Varnam Antimicrobial activity of broad-spectrum agents tested against gram-negative bacilli resistant to ceftazidime: Report from the SENTRY Antimicrobial Surveillance Program (North America, 2001) Diagn. Microbiol. Infect. Dis 44 2002 379 382
13. R.E. Kessler Cefepime microbiologic profile and update Pediatr. Infect. Dis. J. 20 2001 331 336
14. L.A. Mandell, J.G. Bartlett, S.F. Dowell, T.M. File Jr., D.M. Musher, and C. Whitney Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Infectious Diseases Society of America Clin. Infect. Dis. 37 2003 1405 1433
15. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-sixth edition Approved document M7-A6 2003 NCCLS Wayne (Pa)
16. M.M. Newhauser, R.A. Weinstein, R. Rydman, L.H. Danziger, G. Karam, and J.P. Quinn Antibiotic resistance among gram-negative bacilli in US intensive care units JAMA 289 2003 885 889
17. H.S. Sader, D.J. Biedenbach, and R.N. Jones Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001) Diagn. Microbiol. Infect. Dis. 47 2003 361 364
18. H.S. Sader, and R.N. Jones Historical overview of the cephalosporin spectrum: Four generations of structural evolution Antimicrob. Newsl. 8 1992 75 82
19. N. Troillet, M.H. Samore, and Y. Carmeli Imipenem-resistant Pseudomonas aeruginosa: Risk factors and antibiotic susceptibility patterns Clin. Infect. Dis. 25 1997 1094 1098